Cugene Revenue and Competitors
Estimated Revenue & Valuation
- Cugene's estimated annual revenue is currently $2.3M per year.
- Cugene's estimated revenue per employee is $155,000
Employee Data
- Cugene has 15 Employees.
- Cugene grew their employee count by -17% last year.
Cugene's People
Name | Title | Email/Phone |
---|---|---|
1 | Sr. Director, Head Biological Sciences | Reveal Email/Phone |
2 | Director Business Operations & Alliance Management | Reveal Email/Phone |
3 | Director - Business Development, Licensing | Reveal Email/Phone |
4 | Sr. Clinical Trial Manager | Reveal Email/Phone |
5 | Office Manager | Reveal Email/Phone |
6 | Senior Scientist | Reveal Email/Phone |
7 | In Vivo Scientist in Immuno-Oncology | Reveal Email/Phone |
8 | Senior Research Associate | Reveal Email/Phone |
Cugene Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Cugene?
At Cugene, we develop medicines that harness the power of the human immune system to fight disease. Through highly innovative bioengineering, these novel therapeutics will provide specificity and efficacy while limiting unwanted side effects on neighboring healthy tissues. Focusing on areas with great unmet medical needs, Cugene’s team is dedicated to finding a Cure for Life.
keywords:N/AN/A
Total Funding
15
Number of Employees
$2.3M
Revenue (est)
-17%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $3.3M | 15 | -32% | $74.2M |
#2 | $1.3M | 15 | 50% | N/A |
#3 | $1.3M | 15 | N/A | N/A |
#4 | $1.3M | 15 | 36% | N/A |
#5 | $1.3M | 15 | 7% | N/A |